Nurix Therapeutics Inc. Insider Trading

NRIX

Last 12 months

Insiders sold $5.09M and bought nothing on the open market.

78% of the selling was scheduled in advance under 10b5-1 plans. Director Julia P Gregory sold 529K on Oct 14, 68% of their stake, outside a plan. No executive or director has bought shares on the open market in the last two years.

Net open-market

−$5.09M

0 buys · 32 sales

Under a 10b5-1 plan

78%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

None

in the last two years

Get an email when NRIX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 15	Gwenn Hansen Chief Scientific Officer	Sold10b5-1 plan	1,452	$25.00	36K	1.2%	Form 4
Oct 14	Julia P Gregory Director	SoldNo plan	22,583	$23.40	529K	68%	Form 4
Oct 2	Christine Ring Chief Legal Officer	Sold10b5-1 plan	5,786	$23.19	134K	39%	Form 4
Sep 2	Christine Ring Chief Legal Officer	Sold10b5-1 plan 2 parts	5,787	$25.76 average	149K	39%	Form 4
Sep 1	Gwenn Hansen Chief Scientific Officer	Sold10b5-1 plan	1,452	$25.47	37K	1.2%	Form 4
Aug 5	Gwenn Hansen Chief Scientific Officer	Sold10b5-1 plan	4,356	$25.00	109K	3.6%	Form 4
Aug 4	Gwenn Hansen Chief Scientific Officer	Sold10b5-1 plan 2 parts	4,111	$24.36 average	100K	3.4%	Form 4
Aug 4	Hans Van Houte Chief Financial Officer	Sold10b5-1 plan 2 parts	4,761	$24.36 average	116K	11%	Form 4
Aug 3	Christine Ring Chief Legal Officer	Sold10b5-1 plan	16,589	$23.05	382K	65%	Form 4
Jul 30	Hans Van Houte Chief Financial Officer	SoldNo plan	2,845	$23.38	67K	6.0%	Form 4
Jul 30	Christine Ring Chief Legal Officer	SoldNo plan	3,847	$23.38	90K	16%	Form 4
Jul 30	Gwenn Hansen Chief Scientific Officer	SoldNo plan	3,847	$23.38	90K	3.1%	Form 4
Jul 2	Christine Ring Chief Legal Officer	Sold10b5-1 plan	11,008	$23.56	259K	45%	Form 4
Jun 25	Christine Ring Chief Legal Officer	Sold10b5-1 plan	28,935	$20.06	580K	68%	Form 4
Jun 25	Gwenn Hansen Chief Scientific Officer	Sold10b5-1 plan	5,394	$20.00	108K	4.5%	Form 4
Jun 2	Christine Ring Chief Legal Officer	Sold10b5-1 plan	8,148	$16.60	135K	38%	Form 4
May 5	Hans Van Houte Chief Financial Officer	Sold10b5-1 plan 2 parts	14,055	$16.60 average	233K	27%	Form 4
May 4	Christine Ring Chief Legal Officer	Sold10b5-1 plan	8,148	$16.96	138K	31%	Form 4
May 1	Christine Ring Chief Legal Officer	Sold10b5-1 plan	5,394	$16.76	90K	17%	Form 4
Apr 30	Hans Van Houte Chief Financial Officer	SoldNo plan	2,388	$16.65	40K	4.4%	Form 4
Apr 30	Christine Ring Chief Legal Officer	SoldNo plan	3,214	$16.65	54K	9.2%	Form 4
Apr 30	Gwenn Hansen Chief Scientific Officer	SoldNo plan	3,214	$16.65	54K	2.6%	Form 4
Apr 2	Christine Ring Chief Legal Officer	Sold10b5-1 plan	8,148	$15.24	124K	24%	Form 4
Mar 2	Christine Ring Chief Legal Officer	Sold10b5-1 plan	8,148	$15.44	126K	19%	Form 4
Feb 9	Christine Ring Chief Legal Officer	Sold10b5-1 plan	14,261	$16.66	238K	25%	Form 4
Jan 30	Hans Van Houte Chief Financial Officer	SoldNo plan 2 parts	3,661	$16.60 average	61K	7.5%	Form 4
Jan 30	Christine Ring Chief Legal Officer	SoldNo plan 2 parts	4,421	$16.60 average	73K	7.2%	Form 4
Jan 30	Gwenn Hansen Chief Scientific Officer	SoldNo plan 2 parts	4,895	$16.60 average	81K	5.5%	Form 4
Jan 20	Christine Ring Chief Legal Officer	Sold10b5-1 plan	3,760	$18.42	69K	6.9%	Form 4
Dec 18, 2025	Christine Ring Chief Legal Officer	Sold10b5-1 plan 2 parts	3,760	$17.91 average	67K	6.9%	Form 4
Nov 24, 2025	Christine Ring Chief Legal Officer	Sold10b5-1 plan	37,600	$17.07	642K	42%	Form 4
Nov 3, 2025	Hans Van Houte Chief Financial Officer	Sold10b5-1 plan	6,284	$12.56	79K	14%	Form 4
Oct 30, 2025	Hans Van Houte Chief Financial Officer	SoldNo plan	3,130	$12.80	40K	6.7%	Form 4
Oct 30, 2025	Christine Ring Chief Legal Officer	SoldNo plan	3,644	$12.80	47K	6.7%	Form 4
Oct 30, 2025	Gwenn Hansen Chief Scientific Officer	SoldNo plan	4,087	$12.80	52K	5.1%	Form 4
Aug 1, 2025	Hans Van Houte Chief Financial Officer	Sold10b5-1 plan	5,402	$11.03	60K	13%	Form 4
Jul 30, 2025	Hans Van Houte Chief Financial Officer	SoldNo plan	4,304	$12.01	52K	9.5%	Form 4
Jul 30, 2025	Christine Ring Chief Legal Officer	SoldNo plan	3,841	$12.01	46K	8.0%	Form 4
Jul 30, 2025	Gwenn Hansen Chief Scientific Officer	SoldNo plan	4,308	$12.01	52K	5.9%	Form 4
May 2, 2025	Hans Van Houte Chief Financial Officer	Sold10b5-1 plan	6,198	$11.33	70K	16%	Form 4

Oct 1510b5-1 plan
Gwenn Hansen
Chief Scientific Officer · sold 1,452 at $25.00
36K
1.2% of stake
Oct 14No plan
Julia P Gregory
Director · sold 22,583 at $23.40
529K
68% of stake
Oct 210b5-1 plan
Christine Ring
Chief Legal Officer · sold 5,786 at $23.19
134K
39% of stake
Sep 210b5-1 plan
Christine Ring
Chief Legal Officer · sold 5,787 at avg $25.76
149K
39% of stake
Sep 110b5-1 plan
Gwenn Hansen
Chief Scientific Officer · sold 1,452 at $25.47
37K
1.2% of stake
Aug 510b5-1 plan
Gwenn Hansen
Chief Scientific Officer · sold 4,356 at $25.00
109K
3.6% of stake
Aug 410b5-1 plan
Gwenn Hansen
Chief Scientific Officer · sold 4,111 at avg $24.36
100K
3.4% of stake
Aug 410b5-1 plan
Hans Van Houte
Chief Financial Officer · sold 4,761 at avg $24.36
116K
11% of stake
Aug 310b5-1 plan
Christine Ring
Chief Legal Officer · sold 16,589 at $23.05
382K
65% of stake
Jul 30No plan
Hans Van Houte
Chief Financial Officer · sold 2,845 at $23.38
67K
6.0% of stake
Jul 30No plan
Christine Ring
Chief Legal Officer · sold 3,847 at $23.38
90K
16% of stake
Jul 30No plan
Gwenn Hansen
Chief Scientific Officer · sold 3,847 at $23.38
90K
3.1% of stake
Jul 210b5-1 plan
Christine Ring
Chief Legal Officer · sold 11,008 at $23.56
259K
45% of stake
Jun 2510b5-1 plan
Christine Ring
Chief Legal Officer · sold 28,935 at $20.06
580K
68% of stake
Jun 2510b5-1 plan
Gwenn Hansen
Chief Scientific Officer · sold 5,394 at $20.00
108K
4.5% of stake
Jun 210b5-1 plan
Christine Ring
Chief Legal Officer · sold 8,148 at $16.60
135K
38% of stake
May 510b5-1 plan
Hans Van Houte
Chief Financial Officer · sold 14,055 at avg $16.60
233K
27% of stake
May 410b5-1 plan
Christine Ring
Chief Legal Officer · sold 8,148 at $16.96
138K
31% of stake
May 110b5-1 plan
Christine Ring
Chief Legal Officer · sold 5,394 at $16.76
90K
17% of stake
Apr 30No plan
Hans Van Houte
Chief Financial Officer · sold 2,388 at $16.65
40K
4.4% of stake
Apr 30No plan
Christine Ring
Chief Legal Officer · sold 3,214 at $16.65
54K
9.2% of stake
Apr 30No plan
Gwenn Hansen
Chief Scientific Officer · sold 3,214 at $16.65
54K
2.6% of stake
Apr 210b5-1 plan
Christine Ring
Chief Legal Officer · sold 8,148 at $15.24
124K
24% of stake
Mar 210b5-1 plan
Christine Ring
Chief Legal Officer · sold 8,148 at $15.44
126K
19% of stake
Feb 910b5-1 plan
Christine Ring
Chief Legal Officer · sold 14,261 at $16.66
238K
25% of stake
Jan 30No plan
Hans Van Houte
Chief Financial Officer · sold 3,661 at avg $16.60
61K
7.5% of stake
Jan 30No plan
Christine Ring
Chief Legal Officer · sold 4,421 at avg $16.60
73K
7.2% of stake
Jan 30No plan
Gwenn Hansen
Chief Scientific Officer · sold 4,895 at avg $16.60
81K
5.5% of stake
Jan 2010b5-1 plan
Christine Ring
Chief Legal Officer · sold 3,760 at $18.42
69K
6.9% of stake
Dec 18, 202510b5-1 plan
Christine Ring
Chief Legal Officer · sold 3,760 at avg $17.91
67K
6.9% of stake
Nov 24, 202510b5-1 plan
Christine Ring
Chief Legal Officer · sold 37,600 at $17.07
642K
42% of stake
Nov 3, 202510b5-1 plan
Hans Van Houte
Chief Financial Officer · sold 6,284 at $12.56
79K
14% of stake
Oct 30, 2025No plan
Hans Van Houte
Chief Financial Officer · sold 3,130 at $12.80
40K
6.7% of stake
Oct 30, 2025No plan
Christine Ring
Chief Legal Officer · sold 3,644 at $12.80
47K
6.7% of stake
Oct 30, 2025No plan
Gwenn Hansen
Chief Scientific Officer · sold 4,087 at $12.80
52K
5.1% of stake
Aug 1, 202510b5-1 plan
Hans Van Houte
Chief Financial Officer · sold 5,402 at $11.03
60K
13% of stake
Jul 30, 2025No plan
Hans Van Houte
Chief Financial Officer · sold 4,304 at $12.01
52K
9.5% of stake
Jul 30, 2025No plan
Christine Ring
Chief Legal Officer · sold 3,841 at $12.01
46K
8.0% of stake
Jul 30, 2025No plan
Gwenn Hansen
Chief Scientific Officer · sold 4,308 at $12.01
52K
5.9% of stake
May 2, 202510b5-1 plan
Hans Van Houte
Chief Financial Officer · sold 6,198 at $11.33
70K
16% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NRIX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with NRIX

CompareIntrinsic value

BBIOBridgeBio Pharma, Inc.

$74.95+5.97%30

RAREUltragenyx Pharmaceutical Inc.

$16.10-4.05%40

AMPHAmphastar Pharmaceuticals Inc.

$27.72+2.93%60

ARWRArrowhead Pharmaceuticals Inc.

$59.90-0.98%40

PCRXPacira BioSciences Inc.

$36.39+0.00%58

KNSAKiniksa Pharmaceuticals International, plc

$92.24-5.45%71

FOLDAmicus Therapeutics, Inc.

No recent price45

EBSEmergent BioSolutions Inc.

$6.81-5.68%48

Held by ETFs

NRIX is in 47 US ETFs. The largest of them, with NRIX's weight in each:

Spot a number that looks wrong? Check it in NRIX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NRIX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.